产品编号 :
Cas No. :
CAS No. |
129121-73-9 |
|---|---|
中文名称 |
(S)-4-((S)-2-(2-((S)-2-((S)-2-((2S,3R)-2-((S)-1-(L-缬氨酰-L-苏氨酰-L-组氨酰-L-精氨酰-L-亮氨酰-L-丙氨酰甘氨酰-L-亮氨酰-L-亮氨酰-L-丝氨酰-L-精氨酰-L-丝氨酰甘氨酰甘氨酰-L-缬氨酰-L-缬氨酰-L-赖氨酰-L-天冬氨酰-L-天冬酰胺酰-L-苯丙氨酰-L-缬氨酰)吡咯烷-2-羧酰胺基)-3-羟基丁酰胺基)-4-氨基-4-氧代丁酰胺基)-3-甲基丁酰胺基)乙酰胺基)-3-羟基丙酰胺基)-5-(((S)-1-(((S)-1-氨基-1-氧代-3-苯基丙烷-2-基)氨基)-1-氧代丙烷-2-基)氨基)-5-氧代戊酸 |
英文名称 |
(S)-4-((S)-2-(2-((S)-2-((S)-2-((2S,3R)-2-((S)-1-(L-valyl-L-threonyl-L-histidyl-L-arginyl-L-leucyl-L-alanylglycyl-L-leucyl-L-leucyl-L-seryl-L-arginyl-L-serylglycylglycyl-L-valyl-L-valyl-L-lysyl-L-aspartyl-L-asparaginyl-L-phenylalanyl-L-valyl)pyrrolidine-2-carboxamido)-3-hydroxybutanamido)-4-amino-4-oxobutanamido)-3-methylbutanamido)acetamido)-3-hydroxypropanamido)-5-(((S)-1-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid |
别名 |
H-VAL-THR-HIS-ARG-LEU-ALA-GLY-LEU-LEU-SER-ARG-SER-GLY-GLY-VAL-VAL-LYS-ASP-ASN-PHE-VAL-PRO-THR-ASN-VAL-GLY-SER-GLU-ALA-PHE-NH2;CALCITONIN GENE RELATED PEPTIDE (8-37) RAT;ALPHA-CALCITONIN GENE-RELATED PEPTIDE (8-37) (RAT);ALPHA-CGRP (8-37) (RAT);VTHRLAGLLSRSGGVVKDNFVPTNVGSEAF-NH2;VAL-THR-HIS-ARG-LEU-ALA-GLY-LEU-LEU-SER-ARG-SER-GLY-GLY-VAL-VAL-LYS-ASP-ASN-PHE-VAL-PRO-THR-ASN-VAL-GLY-SER-GLU-ALA-PHE-NH2;ALA-CYS-ASP-THR-ALA-THR-CYS-VAL-THR-HIS-ARG-LEU-ALA-GLY-LEU-LEU-SER-ARG-SER-GLY-GLY-VAL-VAL-LYS-ASN-ASN-PHE-VAL-PRO-THR-ASN-VAL-GLY-SER-LYS-ALA-PHE-NH2: ACDTATCVTHRLAGLLSRSGGVVKNNFVPTNVGSKAF-NH2DISULFIDE BRIDGE CYS2-CYS7;α-CGRP (8-37) (mouse, rat) |
标准英文名 |
(S)-4-((S)-2-(2-((S)-2-((S)-2-((2S,3R)-2-((S)-1-(L-valyl-L-threonyl-L-histidyl-L-arginyl-L-leucyl-L-alanylglycyl-L-leucyl-L-leucyl-L-seryl-L-arginyl-L-serylglycylglycyl-L-valyl-L-valyl-L-lysyl-L-aspartyl-L-asparaginyl-L-phenylalanyl-L-valyl)pyrrolidine-2-carboxamido)-3-hydroxybutanamido)-4-amino-4-oxobutanamido)-3-methylbutanamido)acetamido)-3-hydroxypropanamido)-5-(((S)-1-(((S)-1-amino-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-5-oxopentanoic acid |
分子式 |
C138H224N42O41 |
分子量 |
3127.56 |
精确分子量 |
3125.67 |
SMILES |
CC(C)C[C@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(N)=O)C(C)C)[C@@H](C)O)C(C)C)C(C)C)C(C)C |
标准SMILES |
CC(C)[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1C=CC=CC=1)C(N)=O |
用途 |
CGRP-(8-37) is a highly selective CGRP receptor antagonist; it is effective in alleviating mechanical and thermal allodynia in a dose-dependent manner; intrathecal administration of CGRP-(8-37) reverses substance P (SP)-induced decreases in withdrawal latency and significantly increases response latency compared to basal levels. |
InChIKey |
HZKKKBMPFPSSKZ-QZMRZBIOSA-N |
|
|
评论 |
|---|